SCHEMBL240206

SCHEMBL240206

CCCCCCCCCCCCCCCC(=O)NC(C)O

nearest known ligand 0.74

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.74
MEN1 O00255 2/20 0.74
KMT2A Q03164 2/20 0.74
MAPK1 P28482 1/20 0.74
DNM1 Q05193 1/20 0.59
HSP90AA1 P07900 1/20 0.57
ASAH2 Q9NR71 1/20 0.57
ALDH1A1 P00352 1/20 0.55
ASAH1 Q13510 1/20 0.55
ACER2 Q5QJU3 1/20 0.55
NOD1 Q9Y239 1/20 0.54
PLA2G2C Q5R387 1/20 0.54
PLA2G10 O15496 2/20 0.54
THRB P10828 1/20 0.50
CETP P11597 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL594176 1.00 FAAH (0.74) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL308645 1.00 FAAH (0.74) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL16389868 1.00 FAAH (0.74) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL15281949 1.00 FAAH (0.74) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL10600706 1.00 FAAH (0.74) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL875221 1.00 FAAH (0.74) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL8627798 1.00 FAAH (0.74) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL308262 1.00 FAAH (0.74) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL8623658 1.00 FAAH (0.74) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL308684 1.00 FAAH (0.74) FAAHMEN1KMT2AMAPK1DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1040 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4694699-A2 COMPOSITIONS AND METHODS OF CONTROLLING MAMMALIAN SATIETY VitaKey Inc. (US) 2026-02-18 EP claimed
EP-4665327-A1 COMPOSITIONS COMPRISING 3,4-METHYLENEDIOXYMETHAMPHETAMINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF Clearmind Labs Corp. (CA) 2025-12-24 EP claimed
EP-4665348-A1 COMPOSITIONS COMPRISING IBOGAINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF Clearmind Labs Corp. (CA) 2025-12-24 EP claimed
EP-4665317-A1 COMPOSITIONS COMPRISING KETAMINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF Clearmind Labs Corp. (CA) 2025-12-24 EP claimed
EP-4661877-A1 COMPOSITIONS COMPRISING PSILOCYBIN, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES AND USES THEREOF Clearmind Labs Corp. (CA) 2025-12-17 EP claimed
US-20250302773-A1 COMPOSITIONS COMPRISING MEAI AND N-ACYLETHANOLAMINES AND USES THEREOF Clearmind Medicine Inc. (CA) 2025-10-02 US claimed
US-12239634-B2 Methods of treating pruritus CLEXIO BIOSCIENCES LTD. (IL) 2025-03-04 US claimed
WO-2024216228-A2 COMPOSITIONS AND METHODS OF CONTROLLING MAMMALIAN SATIETY VITAKEY INC. (US) 2024-10-17 WO claimed
WO-2024171074-A1 COMPOSITIONS COMPRISING KETAMINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF Clearmind Medicine Inc. (IL) 2024-08-22 WO claimed
WO-2024171075-A1 COMPOSITIONS COMPRISING IBOGAINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF Clearmind Medicine Inc. (IL) 2024-08-22 WO claimed
WO-2008023998-A1 N-ACYLETHANOLAMINES AS WOUND HEALING AGENTS INDUSTRIAL RESEARCH LIMITED (NZ) 2008-02-28 WO claimed
US-20070270496-A1 Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system EPITECH GROUP S.R.L. (IT) 2007-11-22 US claimed
EP-1844784-A1 A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system Epitech Group S.r.l. (IT) 2007-10-17 EP claimed
US-7199082-B1 Composition of an N-acylethanolamine plant hormone of an auxin, a gibberellin or a cytokinin; and a horticulturally-acceptable vehicle; treating and storing cut flowers, Christmas trees, fruits, and other severed plant parts UNIVERSITY OF NORTH TEXAS (US) 2007-04-03 US claimed
EP-1263286-B1 METHODS FOR EXTENDING THE FRESHNESS OF CUT FLOWERS UNIV NORTH TEXAS (US) 2006-02-22 EP claimed
US-20050081311-A1 Pearly-lustre coloring agents for keratin fibers WELLA AKTIENGESELLSCHAFT (DE) 2005-04-21 US claimed
EP-0122151-B1 PRODUCTION OF PRIMARY OR SECONDARY ALCOHOL DERIVATIVES OF PHOSPHOLIPIDS BY THE ENZYMATIC TECHNIQUE MEITO SANGYO KABUSHIKI KAISHA (JP) 1989-02-15 EP claimed
US-4777038-A NONIONIC, STORAGE-STABLE HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1988-10-11 US claimed
US-4312771-A POTASSIUM SALTS OF FATTY ACIDS, FATTY ACID MONOETHANOLAMIDE, AND PROPANEDIOL OR GLYCEROL DUSKIN FRANCHISE CO., LTD. (JP) 1982-01-26 US claimed
US-4039562-A MALEIC ANHYDRIDE, FATTY ALCOHOL, ALKALI METAL SULFITE REWO CHEMISCHE WERKE G.M.B.H. (DT) 1977-08-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050081311-A1 Pearly-lustre coloring agents for keratin fibers KRT18, AKR7A2, ELOVL5 FAAH 496/4885MEN1 4633/4885KMT2A 387/4885
US-20250302773-A1 COMPOSITIONS COMPRISING MEAI AND N-ACYLETHANOLAMINES AND USES THEREOF SLC18A2, PNMT, DBI FAAH 83/4885MEN1 886/4885KMT2A 221/4885
US-20070270496-A1 Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system HCAR2, HCAR1, MYD88 FAAH 329/4885MEN1 1658/4885KMT2A 3832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.